Asthma Clinical Trial
Official title:
Observational Assessment of Baseline Asthma Control as a Susceptibility Factor for Air Pollution Health Effects in African-American Children With Moderate-severe Asthma (Teen AIRE Study)
To determine if baseline asthma control influences susceptibility to pollutant-induced health effects in African-American children with moderate-to-severe asthma.
In the general public, certain sub-populations are at higher risk for adverse health effects
due to air pollution exposure. Asthmatics have been identified as one such susceptible
population due to the observed association of elevated air pollution levels and increased
incidences of acute asthma exacerbations as evidenced by decreased lung function values and
respiratory symptoms, shortness of breath, emergency department (ED) visits, and
hospitalizations (6-13). A study conducted by Mar et al (2004) reported that health outcomes
associated with coarse particulate matter (PM2.5-10) were more notable in children with
asthma than in adults with asthma (14) and a large epidemiological study of asthmatic
children in the Northeastern US showed that asthma morbidity on high ozone days was
consistently highest among children age 6 to 18 years (15). Furthermore, children with
persistent asthma (requiring daily maintenance medication) were shown to be at increased
risk of respiratory symptoms and rescue medication use after ambient ozone exposure compared
to children with mild intermittent asthma (16). Together, these studies demonstrate an
additional level of susceptibility to air pollution in children compared with adults and in
children with persistent asthma compared with mild intermittent asthma.
African-American patients appear to be particularly susceptible to asthma-related
complications, with rates of asthma-related emergency department visits, hospitalizations,
and death approximately 2 to 3 times the rates found in Caucasian subjects (17) .
Furthermore, a higher proportion of African-American asthmatics have poorly-controlled
asthma compared to non-African-American asthmatics (18). In a recent pediatric study, very
poorly controlled asthmatics had an increased risk of asthma-related hospitalization,
emergency department visits, or corticosteroid burst (OR, 6.4; 95% CI, 1.2-34.5) compared
with those whose asthma was under better control over a 2-year period (19).
The goal of this panel study is to determine if African-American children with
poorly-controlled moderate-to-severe persistent asthma are at increased risk for
cardiopulmonary effects as a result of ambient air pollution exposure compared to age- and
race-matched well-controlled moderate-to-severe asthmatic children. The primary cohort for
this panel study will be African-American children between the ages of 12-17 years with
moderate-to-severe asthma (divided between the study populations of poorly-controlled asthma
and well-controlled asthma). Since this study is exclusively focused on an African-American
population, it is not designed to address the effect of race/ethnicity on baseline asthma
control. Volunteers will be recruited primarily from the UNC Pediatric Pulmonary clinic and
the UNC Allergy/Immunology clinic located at Rex Hospital in Raleigh, NC in which Dr.
Hernandez is an attending physician. These volunteers are well-characterized asthmatics
followed regularly by a pediatric pulmonologist (Dr. Ceila Loughlin) and by a pediatric
allergist (Dr. Michelle Hernandez) at the Rex location. In order to ensure that the two
cohorts experience equivalent daily exposures to ambient air pollutants, the study
population will be recruited from a defined geographical region within a reasonable driving
distance of the Rex Hospital and in relative proximity to the state-operated monitoring
station for ambient air pollutants.
Establishing a relationship between asthma control and adverse health outcomes in response
to air pollution exposure will provide health care providers and parents of children with
moderate-to-severe asthma the information necessary to take proactive action on high air
pollution days as they are communicated to the public through color-coded days based on the
National Ambient Air Quality Standards (NAAQS) established by the EPA. If asthma control is
determined in this study to be a risk factor for susceptibility, future work will be
directed toward establishing the mechanism underlying the susceptibility which may then lead
to the potential design of new therapies or intervention strategies.
;
Observational Model: Ecologic or Community, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|